CHILDREN'S ZYRTEC HIVES RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ZYRTEC HIVES RELIEF (CHILDREN'S ZYRTEC HIVES RELIEF).
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. It also inhibits eosinophil chemotaxis and mast cell mediator release.
| Metabolism | Minimally metabolized by hepatic CYP3A4 to a metabolite with negligible activity; primarily excreted unchanged in urine. |
| Excretion | Renal excretion accounts for approximately 70% of the administered dose, primarily as unchanged drug via tubular secretion. Fecal elimination is about 10% with the remainder metabolized. |
| Half-life | Terminal elimination half-life is 8-11 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may increase to 20-30 hours requiring dose adjustment. |
| Protein binding | Approximately 93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.5-0.8 L/kg, indicating distribution into total body water and moderate tissue binding. |
| Bioavailability | Oral bioavailability is approximately 70%, ranging from 60-80% due to first-pass metabolism. |
| Onset of Action | Oral: Onset of antihistaminic effect occurs within 1-2 hours, with peak plasma concentrations reached in 0.5-1 hour. |
| Duration of Action | Duration of action is approximately 24 hours for symptom relief, supporting once-daily dosing. Clinical effects persist for at least 24 hours after a single dose. |
| Molecular Weight | 388.89 |
For adults, the recommended dose of cetirizine (active ingredient in Children's Zyrtec Hives Relief) is 10 mg orally once daily. Route: oral. Frequency: once daily.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | For GFR 10-50 mL/min, reduce dose to 5 mg orally once daily. For GFR <10 mL/min or on dialysis, use 5 mg orally once daily (contraindicated if intermittent hemodialysis). |
| Liver impairment | No specific Child-Pugh adjustment provided in labeling. Use caution in significant hepatic impairment; consider dose reduction to 5 mg orally once daily if concurrent renal impairment. |
| Pediatric use | For ages 6 months to <2 years: 2.5 mg orally once daily. For ages 2 to <6 years: 2.5 mg orally once daily, may increase to 2.5 mg twice daily or 5 mg once daily if needed. For ages 6-12 years: 5-10 mg orally once daily. For ages >12 years: 10 mg orally once daily. |
| Geriatric use | In elderly patients >65 years, start with 5 mg orally once daily due to decreased renal clearance. Monitor for sedation and dizziness. |
| 1st trimester | Limited human data; animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Use only if clearly needed. |
| 2nd trimester | No known risk from oral antihistamines; consider risk-benefit. |
| 3rd trimester | Use near term may cause respiratory depression or withdrawal in neonates; avoid in late pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ZYRTEC HIVES RELIEF (CHILDREN'S ZYRTEC HIVES RELIEF).
| Placental transfer | Cetirizine crosses the placenta; animal studies show fetal exposure. Human data limited but suggests transfer. |
| Breastfeeding | Cetirizine is excreted into breast milk in low concentrations. Manufacturer recommends caution; short-term use is likely compatible. Monitor infant for drowsiness or irritability. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to cetirizine or any componentSevere renal impairment (CrCl < 10 mL/min)End-stage renal disease
| Precautions | May cause drowsiness; avoid driving or operating machinery until effects are known., Use with caution in patients with renal impairment (creatinine clearance <31 mL/min) or hepatic impairment., Avoid concurrent use with alcohol or other CNS depressants., Not recommended for use in children <2 years of age. |
| Food/Dietary | No clinically significant food interactions. Alcohol may potentiate CNS depression; avoid concurrent use. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 (Safer) |
| Teratogenic Risk | First trimester: Limited human data; animal studies not suggestive of increased malformation risk. Second/third trimester: No evidence of teratogenicity; may cause paradoxical CNS stimulation in neonates if used near term. Considered Category B. |
| Fetal Monitoring | No specific routine monitoring required. Observe for maternal adverse effects (somnolence, dry mouth) and neonatal events (irritability, sedation) if used near delivery. |
| Fertility Effects | No evidence of adverse effects on fertility based on animal studies. Human data lacking. |
| Children's Zyrtec Hives Relief contains cetirizine, a second-generation antihistamine. Onset of action is within 1 hour, peak effect at 2-4 hours. Dose adjustment required in renal impairment (creatinine clearance < 30 mL/min). May cause somnolence, albeit less than first-generation antihistamines. Can be used for chronic urticaria but avoid in acute asthma exacerbations. |
| Patient Advice | Take exactly as directed; do not exceed recommended dose. · May cause drowsiness; avoid driving or operating machinery if affected. · For children under 2 years, consult a doctor before use. · Notify physician if symptoms persist beyond 3 days or worsen. · Store at room temperature away from moisture and heat. |